Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Background and Methods: IEC-HS is a hyperinflammatory state with high morbidity and mortality. Effective interventions to reverse the process early in the clinical course may be critical to improve outcomes. We previously examined cytokine differences between IEC-HS and other secondary hemophagocytic lymphohistiocytosis, and found significant differences in the patterns and outcomes.⁽¹⁾ This study examines cytokine profiles (CP) of patients treated with CAR-T from 9/2019 to 3/2024 who developed CRS, MAS-L and IEC-HS. Demographics and lab results were compared among the three groups and correlated with outcomes.

Results: CP was tested in 113 of 366 CAR-T patients: 74 with CRS, 19 with MAS-L, and 20 with IEC-HS. The racial distribution was 93% White/Caucasian, 2% Black or African American, 1% Asian, 1% Native American and 3% other or unavailable. No differences were seen in demographics between groups except a higher percentage of patients with ECOG performance status ≥2 in IEC-HS (p=0.037). Incidence of IEC-HS by disease: 3.6% (7/193) in lymphoma, 5% (8/159) myeloma and 28.5% (4/14) B-acute lymphoblastic leukemia (p=0.0002). Incidence of IEC-HS by CAR-T product: 3% (4/150) in Axi-cel, 23% (6/26) in Brexu-cel, 8% (1/13) in Tisa-cel, 5% each (3/60) in Cilta-cel and Ide-cel, and 0/17 in Liso-cel (p=0.001).

Prior to lymphodepletion, labs were already different among the CRS, MAS-L, and IEC-HS groups: hemoglobin (g/dL: 11.1, 9.6, 8.45); platelets (x10⁹/L: 168, 116, 52.5); ferritin (µg/L: 115, 946, 1944). CP was started when patients needed a second dose of tocilizumab or concern for developing MAS-L/IEC-HS, and continued daily until clinical improvement or resolution of inflammatory state. Tocilizumab and dexamethasone use were similar across groups. Other therapies used were vasopressors (3%, 10.5%, 45%; p<0.0001), Methylprednisolone (20%, 31.6%, 50%; p=0.027), Anakinra (12%, 63%, 85%; p<0.0001), Siltuximab (9.5%, 16%, 30%; p=0.06), Basiliximab (30% of IEC-HS), and continuous veno-venous hemofiltration (30% of IEC-HS).

Among the first CP, the CRS group had lower levels of cytokines (in pg/mL) compared to MAS-L and IEC-HS groups: TNF (31, 62.9, 47.7), IL-10 (29.3, 97.7, 169), IL-18 (794, 1353, 2011), IFN-gamma (74, 281, 250), MCP-1 (689, 2722, 2485.5), MIP-1 alpha (220, 234, 247.5), IL-6 (>315: 45%, 79%, 70%), soluble IL-2R alpha (>4000: 45%, 84%, 70%). The percentage of patients who received anakinra before CP1 were 4% (CRS), 21% (MAS-L) and 25% (IEC-HS) (p=0.007). IL-1 beta was below threshold among all patients who received anakinra in CRS and MAS-L and 75% in IEC-HS, suggesting rapid and effective IL-1 suppression by anakinra except in IEC-HS. Cytokines trends 24 hours and 48 hours after the first CP differed between MAS-L and IEC-HS. MAS-L had decreased TNF (62.9, 40.4, 18.5) and MCP-1 (2722, 355, 104) while these cytokines remained elevated or increased in IEC-HS (TNF: 47.7, 105.5, 62.6; MCP-1: 2486, 2276, 1585). IL-18 was minimally elevated in MAS-L (1353, 1955, 3068) and significantly increased in IEC-HS (2011, 2420, 4048). Notably, CP2 and CP3 levels of these cytokines in IEC-HS were statistically significantly higher than corresponding CPs among CRS and MAS-L. In addition, patients who died with persistent E. faecium bacteremia had higher IL-18 on CP3.

Infections occurred in 43%, 58%, and 85% respectively (p=0.002), including E. faecium bacteremia (3%, 5%, 35%; p=0.0004), CMV viremia (30% of IEC-HS patients vs. 11% of non-IEC-HS; p=0.025), and invasive fungal infections (15% of IEC-HS patients; p=0.0001). Between the IEC-HS and non-IEC-HS groups, day 100 non-relapse mortality was 35% vs. 0 (p<0.0001), day 100 all-cause mortality was 45% vs. 3% (p<0.0001), and E. faecium bacteremia-related deaths were 50% vs. 1% (p<0.0001).

Conclusions: CRS, MAS-L andIEC-HS are known complications of CAR-T. Cytokine-directed therapy can modify the cytokine milieu and control the inflammatory process. However, excess immunosuppression may result in life-threatening infections. Further studies are needed to identify optimal biomarker-guided immunosuppressive strategies to control the inflammatory cascade, while avoiding excess immunosuppression.

References:

1. Leung, Nelson, et al. “Outcomes of patients who received CAR T cell therapy and developed IEC-HS treated with cytokine directed therapy.” (2024): 7516-7516.

Bansal:Kite Pharma: Other: Travel Support. Kenderian:Novartis, Humanigen, MustangBio,: Patents & Royalties; Novartis, Kite/Gilead, Juno/BMS, Lentigen, Humanigen, Morphosys, Tolero, LeahLabs, InCyte, Viracta: Research Funding; Novartis, Kite/Gilead, Juno/BMS, Capstan, Humanigen, Carisma: Membership on an entity's Board of Directors or advisory committees; Kite/Gilead, Novartis, Carisma, Juno/BMS, Humanigen, Luminary: Consultancy. Paludo:Biofourmis: Research Funding; Karyopharm: Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Research Funding. Cook:Geron Corp: Other: Held $600 Geron Stock for one week and sold without profit . Bennani:Pfizer: Membership on an entity's Board of Directors or advisory committees; Acrotech Biopharma LLC: Membership on an entity's Board of Directors or advisory committees, Other: Advisory board. Villasboas Bisneto:Regeneron: Research Funding; Genentech: Research Funding; Epizyme: Research Funding; Enterome: Research Funding; CRISPR: Research Funding; Aptose: Research Funding. Kourelis:Pfizer: Research Funding; Novartis: Research Funding. Wang:InnoCare, AbbVie: Consultancy; Incyte, InnoCare, LOXO Oncology, Eli Lilly, MorphoSys, Novartis, Genentech, Genmab, AbbVie, BeiGene, Merck: Research Funding; Kite: Honoraria; Eli Lilly, LOXO Oncology, TG Therapeutics, Incyte, InnoCare, Kite, Jansen, BeiGene, AstraZeneca, Genmab, AbbVie: Other: Advisory Board. Gertz:Medscape: Honoraria; Abbvie: Other: personal fees for Data Safety Monitoring board ; Dava Oncology: Honoraria; Alexion: Honoraria; Sanofi: Other: personal fees; Janssen: Other: personal fees; Prothena: Other: personal fees; Alnylym: Honoraria; Ionis/Akcea: Honoraria; Johnson & Johnson: Other: personal fees; Astra Zeneca: Honoraria. Kapoor:Janssen: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Research Funding; Regeneron: Research Funding; Angitia Bio: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Kite: Membership on an entity's Board of Directors or advisory committees; X4 Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Loxo Pharmaceuticals: Research Funding; Ichnos: Research Funding; Karyopharm: Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Mustang Bio: Membership on an entity's Board of Directors or advisory committees; Amgen: Research Funding; CVS Caremark: Consultancy; Keosys: Consultancy. Ansell:Pfizer: Research Funding; ADC Therapeutics: Research Funding; Bristol Myers Squibb: Research Funding; SeaGen: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding; Affimed: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Research Funding; AstraZeneca: Research Funding. Kumar:Merck: Research Funding; MedImmune/AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Research Funding; Oncopeptides: Other: Independent review committee participation; Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding; Novartis: Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Dingli:Alexion: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Sorrento: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Apellis: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Genentech: Consultancy; K36 Therapeutics: Research Funding; Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Sandahl:Johnson & Johnson: Consultancy; Pfizer Inc: Consultancy; BioLineRx: Consultancy. Lin:Legend: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Caribou: Membership on an entity's Board of Directors or advisory committees; Regeneron: Consultancy; Pfizer: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Research Funding; NexImmune: Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy; Celgene: Consultancy, Research Funding; Genentech: Consultancy. Leung:AbbVie: Current holder of stock options in a privately-held company; Checkpoint Therapeutics: Current holder of stock options in a privately-held company.